LEAP THERAPEUTICS INC (LPTX) Forecast, Price Target & Analyst Ratings
NASDAQ:LPTX • US52187K2006
2.05 USD
+1.61 (+368.57%)
At close: Nov 12, 2025
1.55 USD
-0.5 (-24.39%)
After Hours: 11/12/2025, 8:00:00 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LEAP THERAPEUTICS INC (LPTX).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
ChartMill Buy Consensus
43.33%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $2.05 to mean target of N/A, Based on 6 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
43.33%
LPTX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about LPTX.
In the previous month the buy percentage consensus was at a similar level.
LPTX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-03-27 | HC Wainwright & Co. | Reiterate | Neutral -> Neutral |
| 2025-01-29 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-01-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-28 | Rodman & Renshaw | Initiate | Buy |
| 2024-05-14 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-19 | Baird | Maintains | Outperform -> Outperform |
| 2024-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-11-20 | Mizuho | Maintains | Buy -> Buy |
| 2023-11-14 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-08-15 | Baird | Maintains | Outperform -> Outperform |
| 2023-08-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-07-13 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-06-23 | Raymond James | Maintains | Outperform -> Outperform |
| 2023-05-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-04-13 | Mizuho | Reiterate | Buy |
| 2023-03-27 | Raymond James | Maintains | Outperform |
| 2023-03-27 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-17 | Mizuho | Maintains | Buy |
| 2023-01-27 | Mizuho | Maintains | Buy |
| 2023-01-18 | HC Wainwright & Co. | Maintains | Buy |
| 2022-11-11 | Raymond James | Maintains | Outperform |
| 2022-08-15 | Raymond James | Maintains | Outperform |
| 2022-07-13 | Raymond James | Maintains | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 24, 2026
PeriodQ4 / 2025
EPS Estimate-$0.20
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q44.86%
Number of Analysts3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
LPTX is expected to report earnings on 3/24/2026. The consensus EPS estimate for the next earnings is -0.2 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 1.5M | 1.5M | 1.224M -100.00% | 40.22M | 83.518M 107.65% | 123.06M 47.35% | 156.6M 27.25% | ||||||||
| EBITDA YoY % growth | -33.404M -8.80% | -28.505M 14.67% | -41.397M -45.23% | N/A -37.08% | N/A -1.23% | N/A -21.95% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -33.451M -8.78% | -28.539M 14.68% | -41.426M -45.16% | -56.986M -37.02% | -89.903M -1.23% | -70.03M -21.93% | -48.277M 31.09% | -40.066M 17.01% | -49.572M -23.73% | -57.963M -16.93% | -21.586M 62.76% | 6.066M 128.10% | 33.97M 460.01% | 56.048M 64.99% | |
| Operating Margin | N/A | -1,902.60% | -2,761.73% | -4,655.71% | N/A | N/A | N/A | N/A | N/A | N/A | -53.67% | 7.26% | 27.60% | 35.79% | |
| EPS YoY % growth | -1.50 -16.28% | -0.55 63.33% | -0.48 12.73% | -4.98 -879.17% | -4.18 -8.09% | -1.86 63.78% | -1.13 38.47% | -0.54 52.25% | -0.56 -3.77% | -0.64 -14.55% | -0.23 63.49% | 0.06 126.09% | 0.37 500.00% | 0.62 69.44% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.20 44.86% | -0.12 66.92% | -0.12 69.40% | -0.13 -65.75% | -0.15 25.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -8.709M 45.99% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
19.23%
EPS Next 5 Year
13.37%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
LEAP THERAPEUTICS INC / LPTX Forecast FAQ
Can you provide the upcoming earnings date for LEAP THERAPEUTICS INC?
LEAP THERAPEUTICS INC (LPTX) will report earnings on 2026-03-24, after the market close.
Can you provide the consensus estimates for LEAP THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of LEAP THERAPEUTICS INC (LPTX) is -0.2 USD and the consensus revenue estimate is 0 USD.